IGF1 and epilepsy: Regarding the opinion that the gene defect could determine all the symptoms, new therapeutic options were suggested for ASD, epilepsy and ID based on the gene defect disturbance, including GABA agonists, modulators of GABA A receptors, modulators of GABA metabolism, glutamate receptor antagonists, insulin-like growth factor 1 and m-TOR inhibitors for ASD–epilepsy comorbidity.